# ITONIS INC.

#### **NEVADA COMPANY**

# **QUARTERLY REPORT**

As of February 28, 2014

# Item 1: The exact name of the issuer and its predecessors.

The exact name of the Issuer is Itonis, Inc.

Name Change history:

- Itonis, Inc. as of December 2, 2005
- Kenchou, Inc. as of July 5, 2005

.

# **Item 2:** The address of its principal executive offices:

22951 Mill Creek Drive

Suite A-1

Laguna Hills, CA 92653 Phone: (949) 200-8887

Email: <u>mark@itonisholdings.com</u> Website: <u>www.itonisholdings.com</u>

#### Item 3: Security Information.

#### A. Par or Stated Value for each class of Securities

Security Symbol: ITNS

CUSIP Number 465733103

Common Stock: 1,000,000,000 authorized, Par Value \$0.001 Preferred Stock: 5,000,000 authorized, Par Value \$0.001

NO CUSIP number for the preferred.

# B. Number of shares or total amount of securities outstanding for each class of securities outstanding

Period end date: February 28, 2014

Authorized Shares: 300M Common Shares, 5M Preferred Shares Outstanding Shares: 926,377,519 Common Shares, 0 Preferred Shares

Public Float: Approx 551,162,197

Number of Beneficial Shareholders: Approx 1 Total number of Shareholders: Approx 662

Period end date: November 30, 2013

Authorized Shares: 1,000M Common Shares, 5M Preferred Shares Outstanding Shares: 852,044,186 Common Shares, 0 Preferred Shares

Public Float: 154,828,864

Number of Beneficial Shareholders: Approx 1

Total number of Shareholders: 662

Period end date: November 30, 2012

Authorized Shares: 1,000M Common Shares, 5M Preferred Shares Outstanding Shares: 777,044,186 Common Shares, 0 Preferred Shares

Public Float: 74,201,087

Number of Beneficial Shareholders: Approx 2

Total number of Shareholders: 662

# C. Transfer Agent

Justeene Blankenship Action Stock Transfer Corp. 2469 E. Fort Union Blvd. Suite 214 Salt Lake City, UT 84121 (801) 274-1088

This Transfer Agent is registered under the Exchange Act. The regulatory authority of the

Transfer Agent is the United States Securities and Exchange Commission.

# **Item 4: Issuance History**

The following shares were issued during the three month period ending February 28, 2014 and the twelve month period ending November 30, 2013.

#### **Common Stock**

#### 2013:

• The Company issued 75,000,000 shares in exchange for consulting services and a note payable and accrued interest with a value of \$20,107.

• The Company refunded \$21,000 in stock payments.

#### 2014:

- The Company issued 106,333,333 shares for \$31,500 in debt
- Executives of the Company returned 80,000,000 shares of stock with a value of \$177,200.
- One of the principals of Paramount Discoveries, Inc., returned 28,000,000 share of common stock for failure to meet certain development milestones.
- The Company issued 80,000,000 shares with a value of \$176,000 for consulting services.

#### Item 5: Financial Statements

- (i) The Annual financial statements are incorporated by reference.
- (ii) The following Annual financial statements are incorporated by reference.
- Balance Sheet for November 30, 2013 and 2012
- Statement of Income for the Year ended November 30, 2013 and 2012
- Statement of changes in stockholders' equity as of November 30, 2013
- Statement of cash flows for the Year ended November 30, 2013
- Financial Notes as of November 30, 2013

# Management's Discussion and Analysis of Plan of Operation

# Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with the financial statements and notes thereto included in this report. The statements contained in this report that are not purely historical are forward-looking statements which would include, but not be limited to, statements regarding our expectations, hopes, intentions or strategies regarding the future. Forward-looking statements include statements regarding: future product or product development; future research and development spending on our product development strategies, and are generally identifiable by the use of the words "may", "should", "expect", "anticipate", "estimates", "believe", "intend", or "project" or the negative thereof or other variations thereon or comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause out actual results, performance or achievements (or industry results,

performance of achievements) expressed or implied by these forward-; looking statements to be materially different from those predicted. The factors that could affect our actual results include, but are not limited to, the following: general economic and business conditions, both nationally and in the regions in which we operate; competition' changes in business strategy or development plans; our inability to retain key employees; our inability to obtain sufficient financing to continue to expand operations; and changes in demand for products by our customers.

# Plan of Operation:

Itonis, Inc. was originally incorporated in 2005 under the name of Kenshou, Inc. Later that year in December of 2005, the company changed its name to Itonis, Inc.

The Company had focused its acquisition efforts in the scientific technology sector with its Paramount Discoveries and AppRocket.com projects, but recently had transitioned into the homeopathic and cannabis industries.

Later in the Summer of 2012, Itonis announced its formation of an Itonis Pharmaceuticals division headed by Dr. Charles Hensley, Ph.D., who created the Zicam® cold remedy. Dr. Hensley and his team has developed an anti-nausea remedy called Emesyl™. As of the filing of this report, the Emesyl™ product is in the final stages of filing an NDC number with the Food & Drug Administration to enable the final manufacturing production. The manufacturer has confirmed that it be able to fill a production batch upon the regulatory finalization.

The Company has also announced a signed agreement with MyECheck, Inc. to license a mobile app to facilitate point of purchase transactions in the medical marijuana, gambling and general retail sectors. MyECheck has projected delivering the app to the Company in May 2014.

The Company has also unveiled its development of a new cannabinoid-based product presently code named as its Cloud9 Project. Cloud9 is expected to be a sublingual product with a unit size range of 100-200mg that can address pain-related ailments.

# Management's Discussion and Analysis of Financial Condition and Results of Operations

The Company is presently focused on developing and launching its first homeopathic anti-nausea product under the guidance of Dr. Charles Hensley. The product is expected to be sold over-the-counter to alleviate mild to moderate nausea. The Company's goal is to manufacture and market its anti-nausea

product during this fiscal year to generate sales revenues. Presently, the Company has placed a manufacturing order for the first batch of its Emesyl<sup>TM</sup> product line.

The Company is positioning itself to receive the final mobile app from MyECheck, Inc. expected in approximately May 2014.

The Company's Cloud9 Project is presently in a final testing phase with Valley Organics, Inc.

# **Results of Operations:**

Itonis is a development stage company. The operating expenses occurred during the three month period ended February 28, 2014 \$212,304 relate mainly to executive compensation of \$199,208, with \$2,086 in legal and \$11,010 in general and administrative charges.

In July 2012, the Company launched its internally-developed web portal for mobile and light computer applications under its <a href="https://www.AppRocket.com">www.AppRocket.com</a> website.

In August 2012, the Company launched a new Itonis Pharmaceuticals division headed by Dr. Charles Hensley, Ph.D. to produce and market over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company has placed a manufacturing order for the first batch of its Emesyl<sup>TM</sup> product line.

In March 2014, the Company signed a licensing agreement with MyECheck, Inc. for the Company to implement a mobile app for point-of-purchase sales transactions in the medical marijuana, gambling, and general retail sectors.

In April 2014, the Company introduced a new cannabinoid-based project that is code named the Cloud9 Project, which is in the final testing phase.

# **Off-Balance Sheet Arrangements**

There are no off balance sheet arrangements.

# **Legal Proceedings**

First Capital filed a claim against Itonis in Miami Dade County, Florida on January 12, 2012 for breach of contract relating to an agreement entered into for shareholder relations. Itonis was not served and therefore did not respond. A default judgment was entered into against Itonis on March 6, 2012. Nothing has happened as of August 31, 2013. Itonis is reviewing its options in this matter.

#### Item 6 Issuer's Business, Products and Services

# A. a description of the issuer's business operations;

The Company operates as a holding company and has embarked upon an aggressive plan to acquire high growth entrepreneurial companies that have established or are expected to establish themselves as leaders and successful enterprises in various market niches.

#### B. Date and State of Incorporation;

The issuer is a Nevada Corporation Incorporated on July 5, 2005.

#### C. the issuer's primary SIC code:

Primary 6719 Secondary 6141

#### D. the issuer's fiscal year end date;

November 30

#### E. principal products or services, and their markets;

In August 2012, the Company launched a new Itonis Pharmaceuticals division headed by Dr. Charles Hensley, Ph.D. to produce and market over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company has placed a manufacturing order for the first batch of its Emesyl<sup>TM</sup> product line. The Company has identified the market for its Emesyl<sup>TM</sup> product line as the general public who suffers from nausea.

In March 2014, the Company signed a licensing agreement with MyECheck, Inc. for the Company to implement a mobile app for point-of-purchase sales transactions in the medical marijuana, gambling, and general retail sectors.

In April 2014, the Company introduced a new cannabinoid-based project that is code named the Cloud9 Project, which is in the final testing phase.

#### **Item 7 Issuer's Facilities**

The Company's corporate headquarters are located in approximately 2,383 square feet of leased office space in Laguna Hills, California pursuant to a lease that expires in August 2018. In the opinion of management, the Company's current space is adequate for its operating needs.

# Item 8 Officers, Directors and Control Persons

A. Officers, Directors and Control Persons. In responding to this item, please provide the following information for each of the issuer's executive officers, directors, general partners and control persons, as of the date of this information statement.

#### A. Officers and Directors

The Management of the Issuer is described in detail and incorporated herein by reference to financial statements filed with the pink sheets

#### Mark Cheung, CEO/President and Director.

Business Address: 22951 Mill Creek Drive, Suite A, Laguna Hills, CA 92653.

Employment History: (Apr 2002 – present) Attorney. Mr. Cheung has more than 20 years of business law and entrepreneurial experience in the legal fields of business litigation and appeals. He has been a name partner at his Irvine, California law firm that has handled numerous business litigation and intellectual property matters, including a trademark case that ended favorably in the U.S. Supreme Court. Through years of litigation matters, Mr. Cheung has confronted unprecedented business operational disputes and relationship issues, providing industry opportunities to enhance and apply problem-solving skills at all levels.

(Jan 2005 – present) Adjunct Professor of Law at Chapman University School of Law.

*Board Memberships/Affiliations:* Board Member, Consumer Credit Counseling Service of Orange County (2001 – present), which is a non-profit organization.

Compensation: Zero in 2010. For the 18 months from January 2011 thru June 2012: 20,000,000 shares of common stock restricted for 12 months, plus 8,000,000 shares common stock that would be subject to that certain registration statement on Form S-1 if filed with the Securities and Exchange Commission for resale.

*Stock Ownership in the Company:* The Company has issued 89,000,000 shares of restricted common stock to Mr. Cheung.

#### **Steve Pidliskey, Vice President/ Secretary**

Business Address: 22951 Mill Creek Drive, Suite A, Laguna Hills, CA 92653.

Employment History: (Aug 1978 – Jan 2011) Project Executive – TSO Alliance Delivery, National Competency Center, Global Technology Services at IBM Corporation (last position held). Mr. Pidliskey has had a 32 ½ year career with

IBM where he has held numerous management positions. He has been responsible for business functions that included regional sales operations, global customer delivery, service support, project management, product planning, complex solution development, and technical sales support.

Compensation: Zero in 2010. For the 18 months from January 2011 thru June 2012: 10,000,000 shares of common stock restricted for 12 months, plus 4,000,000 shares common stock that would be subject to that certain registration statement on Form S-1 to be filed with the Securities and Exchange Commission for resale.

Stock Ownership in the Company: The Company has issued 46,000,000 shares of restricted common stock to Mr. Pidliskey.

#### Donald Jolly, Ph.D., Chief Financial Officer/ Treasurer

Business Address: 22951 Mill Creek Drive, Suite A, Laguna Hills, CA 92653.

Employment History: (Jan 2010 – present) Director of Hyperbaric Medicine at the Center for New Medicine. He operates the hyperbaric treatment and financial aspects of the Center, and also conduct hyperbaric research.

(July 1999 – Jan 2010) Director of Back to Health Program and Director of Hyperbaric Medical Department at the Whitaker Wellness Institute. His responsibilities included hyperbaric therapy orientation and treatment, patient education, and hyperbaric research.

(prior history) Mr. Jolly has more than 20 years' experience in the Finance Industry. He has served at both the board and executive levels within the banking community, holding numerous executive positions ranging from the Vice President of Marketing to the President/CEO of several California banks. His wide array of corporate and retail experience include all aspects of banking operations, loans, marketing, personnel, and customer relations. His founding of a local California bank provided him valuable experience in managing the early developments of a business.

*Board Memberships/Affiliations:* Chairman, Richard A. Neubauer Research Institute, a 501(c)(3) non-profit organization established to further research, medical improvements, and education in hyperbarics. Chairman, Holy Family Institute, a non-profit organization.

Compensation: Zero in 2010. For the 18 months from January 2011 thru June 2012: 6,000,000 shares of common stock restricted for 12 months, plus 2,000,000 shares common stock that would be subject to that certain registration statement on Form S-1 to be filed with the Securities and Exchange Commission for resale.

*Stock Ownership in the Company:* The Company has issued 28,000,000 shares of restricted common stock to Mr. Jolly.

#### Sam Joudeh, Director

Business Address: 22951 Mill Creek Drive, Suite A, Laguna Hills, CA 92653.

Employment History:

(Jan 2011 – present) President of Sam's Tailoring.Com, Inc. He owns and operates an on-line virtual store for the retail sale of designer brand men's wear. This is an offshoot of his family-operated men's wear business that was originally established in 1950.

(1995 – 2011) President of Sam's European Tailoring, Inc. He owned and operated a retail men's wear store.

(1983 – 2011) President of Sam's Tailoring, Inc. He owned and operated a retail men's wear store.

(May 2000 – 2010) President of The Suit Gallery Five Star Men's Wear, Inc. He owned and operated a retail men's wear store.

Board Memberships/Affiliations: None other than his membership on the boards of his other businesses identified above.

Compensation: Zero in 2010. For the 18 months from January 2011 thru June 2012: 10,000,000 shares of common stock restricted for 12 months, plus 4,000,000 shares common stock that would be subject to that certain registration statement on Form S-1 to be filed with the Securities and Exchange Commission for resale.

Stock Ownership in the Company: The Company has issued 46,000,000 shares of restricted common stock to Mr. Joudeh.

#### **B.** Legal - Disclaimer History.

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other misdemeanor offenses):

None.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or

temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities:

None.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

C) I

None.

# C. Beneficial Shareholders

	Snares of	
Name of Beneficial Owner	Common Stock	<u>%</u>
	Owned	
Mark Cheung	89,000,000	10.4

# **Item 9** Third Party Providers

The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure:

1.	Investment Banker:
	None.
2.	Promoters:

#### 3. Counsel:

None.

Owen Naccarato, Esq.

Naccarato & Associates 1100 Quail Street Suite 100 Newport Beach, CA 92660 (949) 851-9261 Owen@owenn.com

#### 4. **Accountant or Auditor:**

Michael Berg, CPA 1562 Portola Drive San Francisco, CA 94127 (415) 515-4090

#### **5.** Public Relations Consultant:

None

#### **6.** Investor Relations Consultant:

None

# 7. Advisory:

None

#### Item 10 Issuer's Certificate

#### I, Mark Cheung, certify that:

- 1, I have reviewed this quarterly disclosure statement of Itonis, Inc.
- 2, Based upon my knowledge, this disclosure statement does not contain an untrue statement of a material fact of omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement, and
- 3, Based upon my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement

April 23, 2014	
/s/ Mark Cheung	
Mark Cheung President	

# I, Donald Jolly, certify that:

- 1, I have reviewed this quarterly disclosure statement of Itonis, Inc,
- 2, Based upon my knowledge, this disclosure statement does not contain an untrue statement of a material fact of omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement, and
- 3, Based upon my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement

April 23, 2014

/s/ Donald Jolly

Donald Jolly

Chief Financial Officer

Itonis Inc.
(formerly "Kenshou Inc.")
Financial Statements and
Footnotes
For the Quarter Ended
February 28, 2014

(1	, , 	February 28, 2014	, No	ovember 30, 2013
Current assets				
Cash	\$	232	\$	2,410
Prepaid expenses		45,875		246,283
Other Assets		- 40.407		30,000
Total current assets		46,107		278,693
Fixed Assets, net of depreciation of \$1,408		2,822		3,174
Intangible Assets-Investment in Paramount		-		640,000
Total assets	_\$_	48,929	\$	921,867
Liabilities and stockholders' deficit				
Current liabilities				
Accounts payable and accrued liabilities	\$	145,190	\$	145,189
Accounts payable - related parties		84,496		76,663
Derivative liability		2,280		3,240
Loan payable		86,687		114,454
Income taxes payable		3,200		3,200
Total current liabilities		321,853		342,746
Total liabilities		321,853		342,746
Stockholders' deficit				
Preferred stock; no par;				
\$.001 par; 5,000,000 authorized; and 0				
and 0 issued and outstanding for the				
periods ended February 28, 2014				
and November 31, 2013		-		-
Common stock;				
\$.001 par; 1.000,000,000 authorized; 930,377	7,519			
and 852,044,186 issued and outstanding for	the			
periods ended February 28, 2014				
and November 30, 2013		930,377		852,044
Additional paid-in capital		13,020,353		13,130,986
Accumulated deficit		(8,055,629)		(7,235,884)
Accumulated deficit during the development sta	age	(6,168,025)		(6,168,025)
Total stockholders' deficit		(272,924)		579,121
Total liabilities and stockholders' deficit	\$	48,929	\$	921,867

# Itonis Inc. (formerly "Kenshou Inc.") Statements of Operations (unaudited)

# For the Quarter and Year Ended

	February 28, 2014		Nove	mber 30, 2013
Revenues	\$	<u>-</u>	\$	
OPERATING EXPENSES				
Legal and professional fees		2,086		15,687
Executive compensation		199,208		966,738
General and administrative		11,010		42,724
Total operating expenses		212,304		1,025,149
OTHER (INCOME) EXPENSE				
Interest expense		-		6,359
Gain on Debt Forgiveness		-		(202,397)
Loss on Investment				
in Paramount		608,400		
Gain on derivative liability		(960)		(56,760)
Total other (income) expense		607,440		(252,798)
Net loss before taxes		(819,744)		(772,351)
Income tax expense		0		800
Net loss	\$	(819,744)	\$	(773,151)
Basic loss per common share		(\$0.00)		(\$0.00)
Basic weighted average common shares		878,710,852		827,044,186

# Itonis Inc. (formerly "Kenshou Inc.") (A Development Stage Company) Statement of Stockholders' Deficit (unaudited)

	Preferre	d Stock	Common S	Stock		Additional Paid-in	A	ccumulated		Accumulated Deficit During the Development	St	Total ockholders'
	Shares	Amount	Shares	Amount		Capital	Deficit		Stage		Deficit	
Balance as of November 30, 2012		\$ -	777,044,186	\$ 7	77,044	\$ 13,154,747	\$	(6,462,733)	\$	(6,168,025)	\$	1,301,033
Net loss for the period								(773,151)				(773,151)
Shares issued for debt and accrued interest			75,000,000		75,000	(2,761)						72,239
Stock Refund						\$ (21,000)						(21,000)
Balance as of November 30, 2013	<u>-</u>	\$ -	852,044,186	\$ 8	352,044	\$ 13,130,986	\$	(7,235,884)	\$	(6,168,025)	\$	579,121
Net loss for the period								(819,745)				(819,745)
Shares issued for debt			106,333,333	1	06,333	(75,833)						30,500
Return of Paramount shares			(28,000,000)	(	(28,000)	(33,600)						(61,600)
Return of executive shares			(80,000,000)	(	(80,000)	(97,200)						(177,200)
Shares issued for consulting services			80,000,000		80,000	96,000						176,000
Balance as of February 28, 2014		\$ -	930,377,519	\$ 9	30,377	\$ 13,020,353	\$	(8,055,629)	\$	(6,168,025)	\$	(272,924)

# Itonis Inc. (Formerly "Kenshou Inc.") Cash Flow Statements (unaudited)

		the Quarter Ended cuary 28, 2014	For the Year Ended November 30, 2013		
Cash flows from operating activities:		uary 20, 2014	November 30, 2013		
Net loss	\$	(819,744) \$	(773,151)		
Depreciation		353	1,056		
Derivative Liability		(960)			
Adjustments to reconcile net loss to net cash in operating activities:					
Stock issued for executive compensation					
Stock issued for legal and professional fees					
Stock issued for general and administrative expenses					
Increase (decrease) in derivative liability			(56,760)		
Changes in operating assets and liabilities					
Current Assets			(27,588)		
Prepaid Expenses		200,408	823,738		
Other Assets		30,000			
Intangible Assets		640,000			
Accounts Payable		(1)	(140,767)		
Accounts Payable Retated Party		7,833	13,515		
Income Taxes Payable			800		
Net cash used in operating activities		57,889	(159,157)		
Cash flows from investing activities:					
Purchase of Fixed Assets			(4,230)		
Cash flows from financing activities:					
Loans		(27,767)	114,454		
Stock Refund			(21,000)		
Stock for Debt		30,500			
Executive Stock returned to Treasury		(177,200)			
Stock Returned by Paramount		(61,600)			
Shares Issued for Consulting Services		176,000			
Sale of stock		<del>-</del>	72,239		
Net cash provided by financing activities		(60,067)	165,693		
Net change in cash		(2,178)	2,306		
Cash, beginning of period		2,410	104		
Cash, end of period	\$	232 \$	2,410		
Supplementary disclosure of cash flow information:					
Cash paid for interest	\$	- \$	-		
Cash paid for taxes	\$ \$	- \$	-		

#### NOTE 1. DESCRIPTION OF BUSINESS AND ACCOUNTING POLICIES

<u>Description of Business</u> – Itonis Inc. (formerly Kenshou Inc.) (the "Company" or "Itonis") was incorporated on July 5, 2005 as Kenshou Inc. under the laws of the State of Nevada. On December 2, 2005, the Company changed its name to Itonis Inc.

The Company operates as a holding company and is undergoing a transformation and has embarked upon an aggressive plan to acquire high growth entrepreneurial companies that have established or are expected to establish themselves as leaders and successful enterprises in various market niches.

In 2013, the Company relocated its headquarter office to an expanded facility within Orange County, California, in conjunction with its development of its pharmaceutical operations.

<u>Development Stage Reporting - During 2006</u> and 2007, the company acquired a wholly owned Czech subsidiary and began promoting the Itonis CZ solution, a video distribution tool. The Company had revenue of \$231,000 through November 30, 2007. In December 2007, continuing its promotion of the video tools, the Company began marketing video distribution exclusively in China and signed several different agreements including Joint Cooperation Agreement with Pilot Media, the acquisition of Aquos Media Limited, and an acquisition agreement with Beijing Tuo Culture Development Ltd. During fiscal year 2008, the Company did not execute all the terms of the agreement with Pilot Media and Aquos Media and did not pursue its business opportunities in China and discontinued its promotion of the video products.

Current management reviewed the activities during 2007 and determined that the Company had commenced operations on its video products and exited the development stage during 2007 and should have begun reporting as a commercial enterprise after that date.

During fiscal years ended 2010 and 2011, Company's management changed the name of the Company to Itonis and management began the process of raising capital and pursuing new businesses for the Company. Because the Company had no significant business operations during this period, it was determined that the Company had reentered the development stage and resumed reporting as a development stage enterprise. Operations prior to December 1, 2010 are reported on a fully operating basis and results are included as accumulated

# NOTE 1. DESCRIPTION OF BUSINESS AND ACCOUNTING POLICIES-CONTINUED

deficit through that date on the balance sheet. Activities subsequent to December 1, 2010 are reported as development stage activities and prior activities have been reported as historical operating activity. These activities are included in "Accumulated deficit" and "Deficit accumulated during development stage" on the balance sheet.

<u>Use of Estimates and Assumptions</u> - The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

<u>Basis of Presentation</u> - These financial statements present the balance sheets and the related statements of operations, cash flows and stockholders' deficit of Itonis, Inc.

Fiscal Periods – The Company's fiscal year-end is November 30.

<u>Cash and Cash Equivalents</u> - For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. The carrying value of these investments approximates fair value.

<u>Accounts Payable related parties</u>- Amounts have been advanced by related parties to fund the operations of the Company. The advances are non-interest bearing, unsecured, and due on demand.

<u>Derivative liabilities</u> – The Company is contractually obligated to issue 1,200,000 more shares than it currently has issued. The values of these shares were originally recorded at their fair market value to determine the cost basis of the underlying transaction. The share liabilities are revalued at the end of each reporting period and the liabilities are adjusted to reflect current market value. The change in fair value is reflected separately in the Company's Statements of Operations. As of February 28, 2014 the fair value of the obligated shares was \$2,280.

<u>Income Taxes</u> - The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, "*Income Taxes*", which requires recognition

# NOTE 1. DESCRIPTION OF BUSINESS AND ACCOUNTING POLICIES-CONTINUED

of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and

liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Earnings (loss) Per Share - The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 "Earnings Per Share", Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

Fair Value of Financial Instruments - Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, requires disclosing fair value to the extent practicable for financial instruments that are recognized or unrecognized in the balance sheet. Fair value of financial instruments is the amount at which the instruments could be exchanged in a current transaction between willing parties. The Company considers the carrying amounts of cash, certificates of deposit, accounts receivable, accounts payable, notes payable, related party and other payables, customer deposits, and short term loans to approximate their fair values because of the short period of time between the origination of such instruments and their expected realization. The Company considers the carrying amount of notes payable to approximate their fair values based on the interest rates of the instruments and the current market rate of interest.

#### Recent Accounting Pronouncements-

The Company has evaluated recent pronouncements through Accounting Standards Updates "ASU" 2014-05 and believes that none of them will have a material impact on the Company's financial position, results of operations or cash flows.

#### NOTE 2. GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of August 31, 2013 the Company has incurred cumulative net losses of almost \$14,200,000. Under current operations the

Company requires capital for its operational and marketing activities to take place. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the company cannot continue in existence.

#### NOTE 3. RELATED PARTY TRANSACTIONS

Management of the Company has made non-interest bearing, unsecured, due on demand cash advances to the Company and has accrued amounts due an officer for services totaling \$ 84,496 as of February 28, 2014. The Company issued 145,000,000 common shares to officers under a 2012 share compensation agreement with a value of \$942,441 which are earned over periods which range from 12-24 months. During the Quarter, officers returned 80,000,000 of these shares with a value of \$177,200 to the Treasury. \$45,875 of compensation has been deferred to the periods after February 28, 2014. The Company also has accrued \$130,000 due an officer for services.

#### NOTE 4. PRIOR ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

During 2012, acting under the advice of legal counsel, the Company reversed amounts due various parties for contractual and accrued obligations. It was determined that \$760,000 due several parties in China was voidable because the underlying contracts were never completed. Additionally, \$214,546 in prior accounts payable due to the Company's prior management was forgiven. Of the

# NOTE 4. PRIOR ACCOUNTS PAYABLE AND ACCRUED LIABILITIES-CONTINUED

\$1,176,943 in prior payables only \$202,397 remained on the Company's books as of November 30, 2012. This amount was written off during 2013.

#### **NOTE 5. LOAN PAYABLE**

The Company issued a promissory note for \$17,873 in exchange for the payment of certain expenses incurred on the Company's' behalf. The note has an interest rate of \$10%. The note is due on demand. As of February 28, 2013, \$2,234 in interest has been accrued on the note. The note was retired in exchange for 75,000,000 million shares of common stock during 2013.

During 2013 the company received \$114,454 in short-term loans from outside parties. These loans are due on demand and are interest free. During the Quarter, the company paid off \$31,500 in these loans through the issuance of 106,333,333 shares of common stock

#### NOTE 6. STOCKHOLDERS' DEFICIT

#### **Preferred Stock:**

The Company has authorized 5,000,000 shares of preferred stock none of which are issued and outstanding as of February 28, 2014 and November 30, 2013.

On June 4, 2012, the Board of Directors of the Company approved the designation of Series A preferred shares which provides voting rights equal to the greater of (i) One Thousand (1,000) votes for each share of Series A Preferred Stock or (ii) the number of votes equal to the number of all outstanding shares of Common Stock, plus one additional vote such that the holders of Series A Preferred Stock shall always constitute a majority of the voting rights of the Corporation.

#### **Common Stock:**

On May 25, 2012, shareholders of record holding over 50% of the issued and outstanding shares of the Company approved the increase in authorized shares from 300,000,000 to 1,000,000,000 shares. There were 930,377,519 and 852,044,186 shares of common stock outstanding as of February 28, 2014 and November 30, 2013, respectively.

#### NOTE 6. STOCKHOLDERS' DEFICIT-CONTINUED

~			4 •
•	nara	Iron	sactions:
. 7	11416	11411	Saturnis.

**Common Stock** 

2013:

- The Company issued 75,000,000 shares in exchange for consulting services and a note payable and accrued interest with a value of \$20,107.
- The Company refunded \$21,000 in stock payments.

#### 2014:

- The Company issued 106,333,333 shares for \$31,500 in debt
- Executives of the Company returned 80,000,000 shares of stock with a value of \$177,200.
- One of the principals of Paramount Discoveries, Inc., returned 28,000,000 share of common stock for failure to meet certain development milestones.
- The Company issued 80,000,000 shares with a value of \$176,000 for consulting services.

#### **NOTE 7. INCOME TAXES**

The provision for income taxes consists of approximately \$800 in State taxes for each of the years ended November 30, 2013 and 2012, respectively.

Deferred tax assets are comprised of the benefits of loss carry forwards for the years ended the November 30, 2013 and 2012 of approximately \$107,000 and \$84,200, respectively. Losses prior to December 1, 2009 were incurred in different industries and in foreign jurisdictions and their use would be limited to offset federal and state income taxes. These losses would also be limited by the change of control provisions in Section 382 and 383 of the Internal Revenue Code.

#### NOTE 7. INCOME TAXES -CONTINUED

Management has concluded that the use of these loss carry forwards would be severely restricted and the effect of these losses is not included in this report.

Deferred taxes arise from temporary differences in the recognition of certain expenses for tax and financial reporting purposes. As of November 30, 2011, the company had significant timing differences for tax reporting purposes for the non-cash recognition of liabilities due for committed shares in excess of authorized shares amounting to \$1,319,710, shares issued for services of \$123,095, and shares issued for

compensation of \$966,738 during 2013 and \$213,780 during 2012. The expenses related to these liabilities are treated as permanent differences between financial and tax reporting.

At November 30, 2013 and 2012, management determined that realization of these loss carryforward benefits is not assured and has provided a valuation allowance for the entire amount of such benefits,

ASC 740 clarifies the accounting for uncertainty in income taxes and prescribes a recognition threshold, measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. Under ASC 740, we are required to recognize in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure. Our policy is to record interest and penalties related to unrecognized tax benefits in income tax expense. There were no unrecognized tax benefits recorded as of November 30, 2013 and 2012.

# NOTE 8. PARAMOUNT DISCOVERIES, INC.

The Company determined that Paramount Discoveries, Inc. was not meeting its development milestones and decided to stop funding the development of Paramount's technologies. As part of this decision, one of the principals of the Paramount returned 28,000,000 shares of common stock that had been issued when the Company acquired the technologies. The Company concurrently wrote off \$640,000 that it had capitalized when Paramount was acquired. The company also abandoned \$30,000 in inventory costs related to Paramount.